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Abstract
Female 129:Stat1-nullmice (129S6/SvEvTac-Stat1tm1Rds homozygous) uniquely develop
estrogen-receptor (ER)-positive mammary tumors. Herein we report that the mammary
glands (MG) of these mice have altered growth and development with abnormal terminal
end buds alongside defective branching morphogenesis and ductal elongation. We also
find that the 129:Stat1-nullmammary fat pad (MFP) fails to sustain the growth of 129S6/
SvEv wild-type and Stat1-null epithelium. These abnormalities are partially reversed by ele-
vated serum progesterone and prolactin whereas transplantation of wild-type bone marrow
into 129:Stat1-nullmice does not reverse the MG developmental defects. Medium condi-
tioned by 129:Stat1-null epithelium-cleared MFP does not stimulate epithelial proliferation,
whereas it is stimulated by medium conditioned by epithelium-cleared MFP from either wild-
type or 129:Stat1-null females having elevated progesterone and prolactin. Microarrays and
multiplexed cytokine assays reveal that the MG of 129:Stat1-nullmice has lower levels of
growth factors that have been implicated in normal MG growth and development. Trans-
planted 129:Stat1-null tumors and their isolated cells also grow slower in 129:Stat1-nullMG
compared to wild-type recipient MG. These studies demonstrate that growth of normal and
neoplastic 129:Stat1-null epithelium is dependent on the hormonal milieu and on factors
from the mammary stroma such as cytokines. While the individual or combined effects of
these factors remains to be resolved, our data supports the role of STAT1 in maintaining a
tumor-suppressive MGmicroenvironment.
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Introduction
The microenvironment of the mammary gland (MG) stromal is a complex mixture of cells,
tissues and molecules that is essential for normal growth and development of the glandular epi-
thelium [1–3]. Development of the MG is also stimulated by hormones acting on the epitheli-
um and the surrounding stroma [4, 5]. The Janus Kinase (JAK)-Signal Transducer and
Activator of Transcription (STAT) pathway plays a central role in this development as a prima-
ry intermediate for growth factor-, cytokine- and hormone-induced signaling [6, 7]. Among
the various STAT molecules, STAT5a and STAT5b play a central role in MG development and
lactation [8, 9]. By contrast, epithelial STAT3 plays a crucial role during involution [10] while
STAT6 has been implicated during gestation-induced MG growth [11]. On the other hand,
STAT1 appears to be functional only in the MG of nulliparous and post-lactational female
mice [6].
The functional analysis of STAT3, STAT5 and STAT6 in the MG has benefited from a
range of genetically modified mouse models [6]. While several models of STAT1 function have
been developed, these have focused primarily on interferon-γ (IFNγ) signal transduction and
transcription. Studies of MG development in mice in the absence of STAT1, either through
germline knockout [12] or somatic knockout conditional to the mammary epithelium [13], did
not identify abnormalities in ductal branching or elongation. However, those studies did not
review the ontogeny of MG development, lactation and involution. Further, developmental
endpoints were not the primary objective of those analyses that focused on tumorigenesis [6].
Studies of mammary tumorigenesis in female Stat1 knockout (Stat1-null) mice describe a
potential tumor suppressor role for STAT1. Indeed, four separate groups have shown that
Stat1-nullmice have an increased susceptibility to mammary tumors in a variety of contexts
[12–15]. Two laboratories used C.129S6(Cg)-Stat1tm1Dlv mice bearing the Stat1-null allele
backcrossed to the Balb/c strain to demonstrate that STAT1 functions as a mammary tumor
suppressor [15, 16]. In those studies tumor formation was induced either via an additional on-
cogene or repeated breeding [15, 16]. Klover et al. developed a targeted mammary epithelial
Stat1 knockout which they crossed with FVB:cNeu to demonstrate epithelial cell intrinsic
tumor suppression by STAT1 [13].
The 129S6/SvEvTac-Stat1tm1Rds homozygous female mice used herein (129:Stat1-null here-
after) [17] spontaneously develop distinctive estrogen receptor (ER) positive mammary tumors
that mimic human luminal intrinsic subtypes of breast cancer [12]. These spontaneous tumors
arise late (latency 18–20 months of age), are ~50% penetrant and have a consistent and unique
phenotype different from the histopathological patterns seen in other tumor suppressor knock-
out models [18]. A potential mechanism for the observed increased risk of MG carcinoma
might stem from changes in the underlying MG during development and aging. We hypothe-
sized that the MG of these mice undergo altered development that reflects an altered stromal
microenvironment. To this end, we initiated a rigorous study of MG development and the con-
tribution of the stromal microenvironment in 129:Stat1-null females. Experimental dissection
and recombination of various elements of the MG and mammary fat pad (MFP) demonstrated
a strong effect of the host environment and a less pronounced epithelial defect in branching
morphogenesis. The loss of STAT1 affected both systemic and local host factors that contribut-
ed to the epithelial abnormalities.
Given that many mouse models of mammary tumorigenesis exhibit abnormal MG develop-
ment at an early age [19], the results of this study provide critical clues to the roles of candidate
genes during neoplastic progression [19, 20].
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Materials and Methods
Mouse Model
129S6/SvEvTac-Stat1tm1Rds (129:Stat1-null) mice [17, 21, 22] were contributed by the Schreiber
lab (RDS), and wild-type (WT) 129S6/SvEv (129SvEvWT) mice were purchased from Taconic
Farms (Hudson, NY). All surgery was performed under Nembutal anesthesia (60 mg/kg) fol-
lowed by post-surgical analgesia (Buprinex; 0.05 mg/kg). All mice were euthanized using an
overdose of Nembutal (120 mg/kg) prior to collection and fixation of tissues.
Histopathology andWhole Mount Preparation
Tissues were fixed in 10% neutral buffered formalin at room temperature for 24 h then placed
in 70% ethanol until processing, which was normally within 24 h. A Tissue-Tek VIP autopro-
cessor (Sakura, Torrance, CA) was used to process tissues that were then embedded in Para-
plast (melting temperature 56–60°C), sectioned to 4 μm and mounted on glass slides. Sections
were stained with hematoxylin and eosin (H&E) for pathologic analysis. For MG whole mount
preparation, the MFPs were dissected, placed onto a glass slide and fixed in 10% neutral buff-
ered formalin. Tissues were further processed in a tissue cassette starting with 70% alcohol for
2 h then transferred to 100% alcohol for another 2 h. Glands were then defatted using three
changes of xylene (30 min, 1 h, 1 h) and then rehydrated through a graded series of alcohol.
After rinsing in running tap water for 30 min, the tissues were stained with hematoxylin for 2
min. Glands were destained in a 1% HCl solution for 15 min, then were placed under running
tap water for approximately 30 min, 70% alcohol for 1 h, 100% alcohol for 1 h, and finally xy-
lene for 1 h. Whole mounts were then submerged in methyl salicylate for storage.
Morphological Analyses
Structural differences in terminal end buds (TEBs) were visualized using a laser scanning based
imaging method described previously [23]. In short, MGs from 129 WT and 129:Stat1-null
were spread on glass slides, fixed with 4% paraformaldehyde in phosphate-buffered saline
(PBS) for 15 min then further fixed overnight in Carnoy’s solution (75% ethanol, 25% acetic
acid). Tissues were stained with carmine alum solution, overnight, followed by destaining with
acidic EtOH (70% EtOH, 0.6 M HCl) for ~2 h until whole mounts showed good contrast.
Whole mounts were dehydrated (30 min each for 80%, 90%, 95% and 100% EtOH) and defat-
ted in xylene overnight prior to mounting with Permount (Electron Microscopy Sciences). To
capture a three-dimensional image of TEBs, whole mounts were assessed using laser scanning-
based tissue autofluorescence/fluorescence imaging (LS-TAFI) with an LSM 710 (Carl Zeiss
Microscopy, Ltd) set to “main dichroic beam splitter” (MBS; 488/561 nm) and “detection
range” (495 to 553 nm for MBS 488 nm; 568 to 728 nm for MBS 561 nm). Scanned images
were analyzed with IMARIS (Bitplane, South Windsor, CT) to quantify each parameter indi-
cated in Fig 1. Total duct length and branch points were measured on images of MG whole
mounts stained with either hematoxylin or carmine. To measure total duct length, greyscale
images were inverted and analyzed with IMARIS imaging software (Bitplane) using the fila-
ment tracing feature.
Microarray Analysis
Microarray analysis (accession number GSE63025) met the 6 critical elements for Minimum
Information About a Microarray Experiment (http://www.mged.org/Workgroups/MIAME/
miame.html). Total cellular RNA was isolated from flash-frozen MGs using TRIzol reagent
(Life Technologies) and a modified protocol that incorporates a second extraction with acid
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phenol/chloroform/isoamyl alcohol (25:24:1, pH 4.3). Total RNA quantity and quality were as-
sessed on a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA) and an Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), respectively. Microarray gene ex-
pression profiling (at the UC Davis Comprehensive Cancer Center’s Genomics Shared Re-
source) was performed by whole-transcript analysis on Affymetrix GeneChip Mouse Gene 1.0
Sense Target (ST) Arrays, which provide coverage for a total of 26,166 RefSeq transcripts from
21,041 individual genes. Briefly, biotinylated sense strand DNA targets were prepared from
100 ng total RNA using the AmbionWT Expression and Affymetrix GeneChip WT Terminal
Labeling Kits according to the manufacturers’ protocols. All downstream microarray process-
ing procedures, including hybridization, washing, staining, and array scanning were performed
according to Affymetrix’s standard protocols. Microarray data analysis was performed with
GeneSpring GX software (Agilent Technologies). Microarray probe intensity values (CEL files)
were background-corrected, summarized, and normalized using the Robust Multi-array Aver-
age (RMA16) algorithm [24] and filtered on raw intensity values for probe sets that exceeded a
threshold of>38. Comparison analysis was performed to identify genes that were differentially
expressed (1.5-fold) between the inguinal MFP of 129:Stat1-null and 129SvEv WTmice. Bio-
logical interpretation of the resulting gene list was performed using the functional annotation
and clustering tools available at the Database for Annotation, Visualization and Integrated Dis-
covery (DAVID) Bioinformatics Resources 6.7 [25]. In brief, these determine gene-gene func-
tional relationships with kappa statistics [26], a novel agglomeration algorithm to organize
them into biological modules, and then to calculate enrichment scores based on Fisher’s Exact
Test [25].
Heat Mapping
Heat mapping was performed with Heat map Builder [27]. The 50 genes with a 2-fold differ-
ence in expression that were either ‘high in 129SvEv WT’ or ‘high in Stat1-null’ as measured by
microarray were heat mapped and color-coded with the ranges indicated on the figure. The cy-
tokine protein profile was also heat mapped to compare the levels of each cytokine.
Mammary Epithelial Tissue Transplantation
In order to provide host transplantation sites, the inguinal MFPs of three-week old 129SvEv
WT and 129:Stat1-null female mice were “cleared” of epithelial tissue as described [28]. Ex-
plants of epithelium-containing MG (1–2 mm pieces) from donor 129SvEv WT or 129:Stat1-
nullmice were dissected from the inguinal MG (between the nipple and lymph node) and
transplanted into the epithelium-cleared mammary fat pads (ECFP) of host mice (left ECFP re-
ceived 129:Stat1-null tissue and right ECFP received 129SvEv WT tissue).
Fig 1. Six week 129:Stat1-nullmammary glands havemore and larger TEBs. Hematoxylin stained whole
mount images of inguinal mammary glands from 6-week-old 129SvEvWT and 129:Stat1-null (Stat1-null)
mice (A). Insets illustrate alterations in TEB between 129SvEvWT and Stat1-nullmice. Scale bar is 2 mm.
Three-dimensional visualization of TEBs from whole mount MG of 6-week-old 129SvEvWT and 129:
Stat1-nullmice using autofluorescence with laser scanning confocal microscopy (B). Surface rendered 3D
images (Ba, Bb) and the orthogonal sections of XY, XZ and YZ planes (Bc, Bd) are shown. Panels on left (Ba,
Bc) are from 129SvEvWTMGs and right (Bb, Bd) are from 129:Stat1-null. Red signal (nuclei; carmine) and
green signal (cell; autofluorescence) are indicated in images. Scale bar is 50 μm. The schematic (Be)
indicates the measuring points for comparing parameters in 3D images of TEBs. The widest TEB diameter is
X (TEB head length). The thickness of TEB at the tip equals Y (body cell layer thickness). X’ (TEB neck
length) was measured at the point equal 2xY from the tip (Bf). TEBs were quantitated when the X > 100 μm.
All data are mean ± SEM (n = 5). *P = 0.0128. 129:Stat1-null gland TEBs (KO) are larger in size as measured
by body layer thickness (Bg, **P = 0.0058) head size (h, **P = 0.0025) and neck size (I, **P = 0.0050).
n = 8. However, the differences in the ratio (X/X’) are not significant (Bj).
doi:10.1371/journal.pone.0129895.g001
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Hormone Treatment
Mice were administered daily SC injections of progesterone (P, 0.5 mg, Acros Organics, New
Jersey) and/or domperidone (DOM, 1.0 mg/Kg, Sigma Chemical Co, St. Louis, MO; to induce
hyperprolactinemia), or estrogen (E, 1 μg, 17β estradiol, Sigma) for 14 d. Both P and E were
suspended in sterile sesame oil, while DOM was dissolved in sterile saline (pH 3.0). Control an-
imals were injected with sesame oil and saline. All animals received the same amount of sesame
oil and saline, every 24 h, for 14 d.
Bone Marrow Grafting
Three week old recipient mice (129SvEv WT or 129:Stat1-null) were irradiated with 1000 rads
in a Model 143–68 Blood Component Irradiator (J.L. Shepard, San Fernando, CA). Bone mar-
row was collected from dissected femurs and tibias of non-irradiated donor mice that had been
given a lethal dose of Nembutal (120 mg/Kg). Bone marrow was flushed into 14 mL culture
tubes containing 5 mL of Hank’s balanced salt solution (HBSS) on ice using an 18 gauge needle
and 3 mL syringe. Crude bone marrow was centrifuged then resuspended in 1 mL of ACK (am-
monium-chloride-potassium) lysing buffer (Gibco, Grand Island, NY) for ~1 min. Samples
from the same donor genotype (129SvEv WT or 129:Stat1-null) were combined, resuspended
in 3 mL HBSS and filtered through a 35 μm filter (BD Biosciences, San Jose, CA). Viable cells
were counted using trypan blue stain. Bone marrow cells were resuspended in sterile PBS (2 x
106 cells/100 μl) for injections into irradiated recipients. Recipients were injected via tail vein
with 200 μL of bone marrow preparation fromWT or 129:Stat1-nullmice. After injection, re-
cipient mice were given Sulfatrim PO with an active dose between 8–24 mg/kg/d for a period
of 10 d. Bone marrow eradication and “take” were documented by qPCR of gDNA (see S1 Text
for details of materials and methods) from peripheral blood, which showed that all surviving
animals had complete engraftment of the donor marrow without residual host marrow (data
not shown).
Immunohistochemistry (IHC)
Antigen retrieval was performed for 45 min with citrate buffer at pH 6.0 in a Decloaking
Chamber (Biocare Medical, Concord, CA) at 125°C and 15 psi. Slides were blocked with nor-
mal goat serum then incubated with a rabbit monoclonal anti-CD3 (1:1000; Clone [Sp7], Cata-
log number Ab16669, Batch number GR125527-1, Abcam, Cambridge, MA) overnight at
room temperature in a humidified chamber, followed by a biotinylated goat anti-rabbit second-
ary antibody (1:1000). The Vectastain ABC Kit Elite Kit and a diaminobenzidine Peroxidase
Substrate Kit (Vector Labs, Burlingame, CA) were used for amplification and visualization of
signal, respectively. Mouse spleen and thymus were used as positive controls for CD3 staining.
Tumor Biopsy and Cell Transplantation
For tumor growth studies, biopsies (1–2 mm pieces) of primary tumors from 129:Stat1-null
mice were transplanted into the intact inguinal MG of 6–8 week old 129SvEv WT or 129:
Stat1-nullmice. Following transplantation, mice were palpated twice weekly to monitor for
tumor appearance. For transplantation of a 129:Stat1-nullmammary tumor cell line, SSM2
cells [12] (hereafter designated SSM2UCD) were used. SSM2UCD cells were grown in the appro-
priate culture media supplemented with 10% fetal bovine serum [12]. Nearly confluent (80%)
cultures were trypsinized, washed 3 times with PBS, and counted. Cells were stored in liquid ni-
trogen until use and were of relatively low passage number (12–27). A bolus of previously cul-
tured cells (3 x 104) was injected into the uncleared inguinal MG of 6–8 week old 129SvEv WT
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or 129:Stat1-nullmice. Two weeks after injection, tumors were removed and processed for his-
tology and IHC.
Conditioned Medium Preparation
129SvEv WT and 129:Stat1-null inguinal MGs were cleared at 3 weeks of age as described
above. At 10 weeks of age, conditioned medium (CM) was prepared from the ECFPs of these
mice by dicing them into fragments (~8 mm3) and incubating them in serum-free Dulbecco's
modified Eagle medium (DMEM) (7.5 mg tissue/mL) for 48 h at 37°C. A basal medium was
prepared by incubating serum-free DMEM for 48 h at 37°C in the absence of ECFP. Both CM
and basal medium were subsequently filtered (0.22 μm) and either used immediately in experi-
ments or stored at -20°C. Some CM and basal medium was concentrated using centrifugal
filters (Amicon ultra, Millipore, Billerica, MA) for mouse cytokine/chemokine assay experi-
ments, or for storage at -80°C.
Comma-1D cells were maintained in growth media (DMEM/F12, 2% fetal bovine serum,
10 μg/mL bovine insulin, 5 ng/mL recombinant human epidermal growth factor, penicillin/
streptomycin). Cells (3000/well) were plated into 96-well plates 24 h before the start of the
growth assay (day 0). A standard curve was created by plating known quantities of cells (0–
50,000/well) before quantifying final cell number on day 0 using a methylene blue assay [29].
Following a wash with PBS, media were changed to basal media or CM on day 0, with another
medium change on day 2. Cells were then fixed in 10% formalin, stained for 35 min with 1%
methylene blue, washed using 0.01 M borate buffer (pH 8.5) and the blue stain eluted from the
cells with a 1:1 mix of 95% ethanol and 0.1 M HCl. The plates were read at 665 nm. Blank wells
did not contain cells but were subjected to the entire fixing and staining process, and their aver-
age absorbance subtracted from all wells.
Multiplex Cytokine/Chemokine Assay
AMilliplex MAP 32-analyte kit for the analysis of mouse cytokines/chemokines (EMDMilli-
pore) was used for measuring 32 cytokines and chemokines simultaneously in each sample.
The MAP system is based on unique populations of 100 different, individually identifiable
microbead sets coupled to an antibody specific to a cytokine or chemokine that captures the
relevant analyte in the sample prior to detection using a second, biotinylated antibody specific
to each respective analyte [30]. Multiplex assays were performed according to the manufactur-
er’s instructions. Data for each of the analytes were collected as median fluorescent intensity
(MFI) that was used to calculate analyte concentrations in pg/mL using the software package
BioPlex Manager 5.0 (Bio-Rad) as previously described [31].
Statistical Analysis
Pairwise comparisons between means or least square means were analyzed by Student’s t test.
Parameter means for ductal length and branching points were statistically compared using
GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA). For COMMA 1D cell prolif-
eration studies, statistical significances were tested by 2-way ANOVA.
Ethics Statement
Mice were maintained and housed in a UC Davis animal facility and handled in strict accor-
dance with the guidelines described by the Association for Assessment and Accreditation of
Laboratory Animal Care International and an Institutional Animal Care and Use Committee
of the University of California, Davis approved protocol (protocol numbers 17604 and 16642).
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Results
129:Stat1-nullMice Exhibit Abnormal Mammary Gland Growth and
Development
129:Stat1-null females are capable of nursing pups that thrive and have normal appearing milk
in their opaque stomachs. Whole mounts of MGs from gestating and lactating females were
grossly normal, where MGs from post-partum females had no obvious structural or develop-
mental abnormalities (S1 Fig). By contrast, nulliparous 129:Stat1-nullmice had delayed and
abnormal MG growth and development relative to 129SvEv WTmice. Whole mounts of the
MG from 129:Stat1-nullmice at 6 weeks of age had larger and more abundant TEBs than the
129SvEv WT (Fig 1A) and showed greater variation in ductal elongation, ranging from quite
stunted (not shown) to normal elongation (Fig 1A). LS-TAFI [23] revealed that the neck region
of the TEB from 129:Stat1-nullmice was surrounded with an extended zone of disorganized
small stromal cells that were absent in the proximity of TEB from 129SvEv WTmice (Fig 1B).
Quantitative analysis of three dimensional reconstructions verified that the TEB in 129:Stat1-
nullmice were more numerous (Fig 1B and 1F) and larger than in 129SvEv WTmice and had
longer neck regions (Fig 1B, 1G, 1H and 1I).
In mammary gland whole mounts of mice at 12 weeks of age it was observed that all 129:
Stat1-nullMGs extended into their native MFPs but seemed to lag behind those from their
129SvEv WT counterparts, and rarely reached the end of the fat pad (S2 Fig). The 129SvEv WT
MG appeared to have a higher density of ductal outgrowths and more branching than the 129:
Stat1-nullMG (Fig 2A) and so we tested this hypothesis by quantitative image analysis. This re-
vealed a shorter overall length of the ductal network in the 129:Stat1-nullMG (P = 0.0003) but
no significant differences in the frequency of branch points in the developing 129SvEv WT and
129:Stat1-nullMGs (Figs 2B and 1C).
Serum samples from selected cohorts were analyzed by the Vanderbilt University Mouse
Hormone Core Laboratory for E, P, prolactin (PRL) and insulin levels. The differences between
129SvEv WT and 129:Stat1-null were not statistically significant (S3 Fig). Necropsies did not
reveal significant gross or microscopic differences between the developing 129SvEv WT and
129:Stat1-null female pituitaries, ovaries and uteri (data not shown). The estrus cycle of each
mouse was evaluated by examining the vaginal histology but had no apparent influence on
mammary gland development.
129:Stat1-NullMammary Fat Pad fails to support Epithelial Growth
without Exogenous Hormones
Heterologous transplantation was used to define the growth and developmental impacts of epi-
thelial cell intrinsic factors versus the host microenvironment, including the MFP, bone mar-
row and endocrine/paracrine compartments. Simultaneous control autologous and cross
“reciprocal” transplantation of 129SvEv WT and 129:Stat1-nullmammary epithelium into
129SvEv WT (Fig 3A for experimental design) and 129:Stat1-null host ECFPs were performed
with each recipient mouse hosting both 129SvEv WT and 129:Stat1-null epithelium.
Epithelial transplants were examined for ductal outgrowth 4 weeks after transplantation
using hematoxylin stained whole mounts (Fig 3B). “Take” rates (successful transplants) and
statistical comparisons between groups are recorded in S1 and S2 Tables, respectively. Trans-
plants of 129SvEv WT donor and 129:Stat1-null donor epithelia grew into the mammary MFP
when transplanted into the 129SvEv WT host (Panels a and e in Fig 3B). However, the 129:
Stat1-null host supported fewer takes (S1 Table) and less outgrowth of the transplanted 129:
Stat1-null donor epithelium as compared to the transplanted 129SvEv WT donor epithelium
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Fig 2. 129:Stat1-null have diminished ductal length.Comparison between 129SvEvWT and 129:
Stat1-null (Stat1-null) glands indicated that the Stat1-null glands had less ductal elongation. (A) Whole mount
images of inguinal mammary gland from (a) 129SvEvWT and (b) Stat1-null (see S2 Fig for low power images
of mammary gland whole mounts). Scale bar is 2 mm. (B) Total ductal length and branching points were
measured on photo images of whole mount mammary glands stained with either hematoxylin or carmine red.
For measuring total ductal length, images were analyzed with IMARIS imaging software using the filament
tracing feature. Branching points were manually counted on ducts within 2 mm of end buds. (C) Quantitative
analyses for total ductal length (left) and the number of branches (right) shows that Stat1-null (KO) glands
Abnormal Mammary Development in STAT1-Null Mice is Stroma-Dependent
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(Compare panels b and f in Fig 3B). Interestingly, the 129:Stat1-null epithelial transplants ex-
hibited equal total duct length and significantly greater branching (P = 0.0157) in equal-sized
fat pads in the 129SvEv WT ECFP compared to the autochthonous WT transplants (Fig 3C).
This finding initially suggested that the 129:Stat1-null epithelium does not necessarily have an
intrinsic defect. However, later studies using different experimental variables support an intrin-
sic epithelial defect.
Given that growth and development of the native MG in 129:Stat1-null females appeared to
be rescued during pregnancy, and there is notable cooperatively between the actions of P and
PRL during MG growth [32], the ability of P plus DOM (PDOM) to rescue the impaired
growth of the transplants of 129:Stat1-null epithelium was examined. Exogenous E, P, DOM or
PDOM were administered daily for two weeks to 129SvEv WT and 129:Stat1-null host mice
bearing contralateral transplants of 129SvEv WT and 129:Stat1-nullmammary epithelium.
Exogenous PDOM stimulated the growth of the donor MG epithelium in both 129SvEv WT
and 129:Stat1-null hosts (Panels c, d, g, h in Fig 3B). The effect of E was similar to that induced
by PDOM, whereas there was no effect when the host mice were treated with P or DOM alone
(S4 Fig). Growth parameters (total ductal length and branching points) were enhanced in most
transplants treated with PDOM (Fig 3C). Branching remained lower in 129:Stat1-null epitheli-
um transplanted into either 129:Stat1-null or 129SvEv WTMFP even after PDOM treatment
stimulated growth. This result suggests that the 129:Stat1-nullmammary epithelium does have
an intrinsic, albeit minor but statistically significant, defect in branching morphogenesis (Fig
3C). The results with PDOM treatment confirm, extend and reinforce the prior observations
that pregnancy rescues the mammary phenotype in the native gland (S1 Fig).
129:Stat1-nullMGMicroarray Profile Differs fromWild-Type
Microarray analysis revealed significant (1.5-fold) differences in mRNA expression for vari-
ous genes in the MGs from either 129SvEv WT (Fig 4A) or 129:Stat1-nullmice (Fig 4B), as can
also be represented by heat maps. As expected, genes related to STAT1 function (e.g. IDO1,
Indo1) had significantly lower expression in MGs from 129:Stat1-nullmice. The expression of
eosinophil associated ribonuclease (Ear) genes (Ear1, Ear2, Ear10, Ear11) was significantly
higher in 129:Stat1-nullMGs while the expression of genes relating to monocytes [33] also sig-
nificantly differed between 129SvEv WT and 129:Stat1-null. The expression of calcitonin-asso-
ciated peptide (Calca) mRNA had the highest elevation in 129:Stat1-null glands along with
other genes related to reduction-oxidation pathways, suggesting metabolic deficiency or dysre-
gulation. To further investigate which biological events are involved in the 129:Stat1-null
glands, DAVID functional cluster analysis was performed (Fig 4C). The lists of genes from this
analysis also highlighted the involvement of immune cell related activities in 129:Stat1-null
mice (immune response, leukocyte activation, immune system development, inflammatory re-
sponse, etc.) consistent with previous studies demonstrating that 129:Stat1-nullmice are im-
munodeficient [34–36]. As expected, Stat1mRNA was markedly down-regulated while
expression of various other Stat and Jak genes was differentially altered up and down when the
129:Stat1-nullMG was compared with the 129SvEv WT (S5 Fig).
have significantly (***P = 0.0003) shorter total ductal length. The number of branching points within 2 mm
ductal ends was not significantly different between 129SvEvWT and Stat1-null glands. Data are mean ± SEM
(n = 6).
doi:10.1371/journal.pone.0129895.g002
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Fig 3. 129:Stat1-nullmammary fat pads impede epithelial transplant growth that is restored by
exogenous hormones. Schematic depicting transplantation protocols between 129SvEvWT and Stat1-null
glands and treatment with hormones (A). Inguinal mammary glands from 3-week-old host females were
cleared of endogenous epithelium, while epithelium from donor 129SvEvWT and 129:Stat1-null (Stat1-null)
mammary glands were transplanted into each epithelium-cleared fat pad in host mice 1 week after clearing
surgery. Host mice were injected daily with PDOM from 5 to 7 weeks of age. Hematoxylin-stained whole
Abnormal Mammary Development in STAT1-Null Mice is Stroma-Dependent
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Transplanted Wild-Type Bone Marrow does not Rescue 129:Stat1-null
Epithelial Growth
The 129:Stat1-nullmice are immunologically impaired with known defects in natural killer
(NK) cells and macrophages [34–36]. Cells derived from the bone marrow, including immune
cells and particularly monocytes/macrophages, are known to facilitate MG development [37].
In order to determine if the 129:Stat1-null host defect could be attributed to bone marrow-de-
rived cells, simultaneous bone marrow and MG reciprocal transplantations were performed
(Fig 5). Briefly, lethally irradiated 129:Stat1-nullmice were reconstituted with bone marrow
from 129:Stat1-null (control) or 129SvEv WTmice, and then served as transplant recipients
mount images of reciprocally transplanted mammary glands with or without hormone treatment (B).
Mammary glands in host 129SvEvWT (a, c, e, g) and Stat1-null (b, d, f, h) mice with donor epithelium from
129SvEvWT (a, b, c, d) and Stat1-null (e, f, g, h) mice are shown. Mammary glands from PDOM treated mice
(c, d, g, h). White asterisks in b and f indicate approximate locations of transplantation sites. Quantitative
analyses of the ductal network (C). The left panel graph indicates the total ductal length of mammary glands
in each experiment (WT vs. KO for each treatment). Data are mean ± SEM, **P = 0.0026, ***P = 0.0005.
The right panel graph is the analysis for the number of branching points. **P<0.01, ***P<0.001.
doi:10.1371/journal.pone.0129895.g003
Fig 4. 129:Stat1-nullmammary gland expressionmicroarray profiles indicate down-regulation of
STAT1-related pathways with up-regulation of eosinophil genes.Gene expression microarrays were
performed using RNA extracted from 129SvEvWT and 129:Stat1-null (Stat1-null) mammary glands (MG).
The 50 genes > 2-fold higher in (A) 129SvEvWTMG and (B) Stat1-nullMG are indicated in the heat maps
(WT vs. Stat1-null). DAVID functional clustering (C) showed increased representation of immune cell related
processes (immune response, leukocyte activation, immune system and development, inflammatory
response, etc.), consistent with processes known to be affected by the loss of STAT1.
doi:10.1371/journal.pone.0129895.g004
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for contralateral 129:Stat1-null and 129SvEv WT epithelial MG transplants. Similarly, irradiat-
ed 129SvEv WTmice were reconstituted with either 129SvEv WT (control) or 129:Stat1-null
bone marrow, and then served as recipients for simultaneous 129:Stat1-null and 129SvEv WT
epithelial MG transplants.
All surviving animals had complete engraftment of the donor marrow without residual host
marrow (data not shown). The 129:Stat1-null hosts showed limited growth of the transplanted
mammary epithelium, which did not improve with transplantation of 129SvEv WT bone mar-
row. Additionally, no change in MG growth was recorded in the 129SvEv WT hosts
Fig 5. Bonemarrow grafting does not alter 129:Stat1-null epithelial outgrowth.Hematoxylin-stained inguinal mammary gland whole mounts from
129SvEvWT and 129:Stat1-null (Stat1-null) mice. Briefly, lethally irradiated 129SvEvWT (A, B, C, D) and Stat1-null (E, F, G, H) were reconstituted with bone
marrow (BoMa) from 129SvEvWT (A, B) or Stat1-null (C, D) and were transplant recipients for 129SvEvWT (B, D, F, H) and Stat1-null (A, C, E, G) mammary
gland epithelium. The Stat1-null hosts show limited mammary transplant outgrowth, which did not improve with 129SvEvWT bone marrow transplantation.
Additionally, no change in mammary gland outgrowth was seen in the 129SvEvWT hosts transplanted with Stat1-null bone marrow.
doi:10.1371/journal.pone.0129895.g005
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transplanted with 129:Stat1-null bone marrow (Fig 5). Taken together, these experiments indi-
cated that the mammary phenotype could not be rescued or created using transplanted bone
marrow alone.
Growth of Neoplastic Transplants is Impaired in 129:Stat1-null Hosts
STAT1 was previously shown to function as a tumor suppressor [12–16, 38]. Given our data
indicating that STAT1 functions in the MGmicroenvironment to regulate growth of the nor-
mal epithelium, we performed experiments to assess the effects of this microenvironment on
tumor cell growth. Three different primary MG tumors that arose in 129:Stat1-nullmice were
transplanted bilaterally into inguinal MFPs of 129SvEv WT and 129:Stat1-null recipient mice.
Seven weeks post transplantation, the volume of resulting MG tumors in 129SvEv WT hosts
was almost 10 times that of tumors grown in 129:Stat1-null hosts (Fig 6). Thus, the 129:Stat1-
null local or systemic environment poorly supports the growth of transplanted primary tumor
cells and suggests that the tumor suppressor action of STAT1 in the microenvironment/host is
not functional or effective.
To further define differences in the host response to mammary epithelium, a 129:Stat1-null
epithelial tumor cell line SSM2UCD [39] that had been transplanted into 129SvEv WT and 129:
Stat1-null gland-intact MFPs was examined by histology and immunohistochemistry (Fig 7).
SSM2 UCD tumors transplanted into the 129:Stat1-nullMG showed a consistent and character-
istic granulocytic infiltrate with rare CD3+ cells and other scattered mononuclear cells (Fig
7H). In contrast, transplants into 129SvEv WTMG were characterized by mononuclear, pre-
dominantly CD3+ lymphocytic infiltrates with relatively sparse granulocytes (Fig 7G). Howev-
er, 129:Stat1-null hosts that were pretreated for two weeks with PDOM and then immediately
implanted with SSM2UCD cells showed an intermediate response with a mononuclear host in-
filtrate with more CD3+ cells and decreased granulocytes (Fig 7I). These host responses to
transplanted tumors are consistent with the known immunological imbalance in 129:Stat1-null
Fig 6. 129:Stat1-null fat pads poorly support growth of transplanted tumors. Tumor volume changes in
mammary glands of 129SvEvWT or 129:Stat1-null (Stat1-null) host mice over time. Explants of three primary
mammary gland tumors from Stat1-nullmice were transplanted into inguinal mammary glands of five
129SvEvWT or Stat1-null hosts. Tumors were measured by caliper twice weekly for 7 weeks. Tumor
volumes in 129SvEvWTmice increased 10-fold faster than those in Stat1-null hosts. Data are mean ± SEM
(n = 5), ***P<0.001. Each horizontal black bar represents the mean of tumor volumes.
doi:10.1371/journal.pone.0129895.g006
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mice [22] and the expression microarray analysis of the respective intact mammary fat pads
which show increased levels of granulocyte related RNA (Fig 4).
129:Stat1-nullMammary Fat Pads are Growth Factor Deficient
Transplantation of both neoplastic and normal mammary epithelium into 129:Stat1-null hosts
resulted in retarded cell growth relative to that in the 129SvEv WT host, suggesting that the
129:Stat1-nullmicroenvironment might be deficient in one or more growth-regulating factors.
We first determined the growth response of SSM2UCD cells and COMMA-1D cells (a pheno-
typically normal BALB/c mammary epithelial cell line [40]) to CM prepared using ECFPs from
129SvEv WT control, 129:Stat1-null, and “rescued” 129:Stat1-nullmice treated with PDOM.
The SSM2UCD cells grown in 129SvEv WT CM were assessed by immunofluorescence for
Ki67 (Fig 8A) that revealed a higher growth rate compared to those grown in 129:Stat1-null
CM or basal media (Fig 8B). The SSM2UCD cells cultured in 129:Stat1-null CM showed less co-
hesion compared to cells cultured with CM prepared from the MG of 129SvEv WTmice (Fig
8C and 8D, merged). SSM2UCD cell clusters were more extensive when cultured in 129SvEv
Fig 7. Differing host responses between 129:Stat1-null and 129SvEvWT to transplanted tumor cells.
The SSM2UCD tumor cell line derived from a 129:Stat1-null (Stat1-null) mammary gland tumor was
transplanted into intact mammary glands of 6-week-old 129SvEvWT (A, D, G), Stat1-nullmammary glands
(B, E, H), and mammary glands of Stat1-nullmice treated with PDOM (C, F, I). The SSM2 tumors were
harvested and processed for histopathological review two weeks after transplantation. Upper 3 panels (A, B,
C) show low magnification of H & E-stained transplants after 2 weeks; middle 3 panels (D, E, F) show anti-
CD3 staining. Note that the most intense and wide-spread CD3+ staining is found around and in the SSM2
tumor cells in the 129SvEvWT host. The lower 3 panels (G, H, I) are high magnification of H & E-stained
areas of A, B and C, respectively. In G, arrowheads indicate monocytes suggesting a general mononuclear
response in the 129SvEvWT. In H, arrows point to granulocytes and suggest that the SSM2 tumors have a
general granulocytic host response in the Stat1-null. In I, the presence of monocytes (arrowhead) and
granulocytes (arrow) suggests an intermediate immune response in Stat1-null hormone treated
(PDOM) hosts.
doi:10.1371/journal.pone.0129895.g007
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WT compared to 129:Stat1-null CM with distinctions in cell-cell junctions (ZO1 staining),
focal adhesions (vinculin staining), and organization of the actin cytoskeleton (Fig 8C and 8D).
COMMA-1D cells showed minimal growth in 129:Stat1-null CM when compared to their
growth in serum-free basal media (Fig 9A). In contrast, the CM from 129SvEv WT ECFPs
stimulated growth of COMMA-1D cells [41], with a 24 h doubling time of 2 d (Fig 9A). Inter-
estingly, the CM from 129:Stat1-null ECFPs pretreated with PDOM stimulated the growth of
COMMA-1D cells to an extent similar to their response to 129SvEv WT CM (Fig 9A).
Profiles of Conditioned Media Indicate Reduced Cytokine Levels in the
Stat1-nullMammary Fat Pad
Cell-free CM stimulated differential growth and morphological phenotypes of epithelial cells,
suggesting a role for diffusible molecules such as chemokines/cytokines from the MFP. The
gene expression profiles from intact MFP, alongside the results from the multiplexed protein
Fig 8. Stat1-null fat pad conditioned media poorly supports tumor cell line proliferation. Cell
proliferation of SSM2UCD cells treated with CM from epithelium-cleared fat pads (ECFP) of 129SvEvWT and
129:Stat1-null (Stat1-null) mice is demonstrated with Ki67 staining (A). Immunofluorescence staining for Ki67
(red) and DAPI (blue) shows the growth proportion of SSM2UCD cells cultured in conditioned media (CM) from
129SvEvWT ECFP (a, WT), CM from Stat1-null ECFP (b, KO) or basal media (c, BM). The percentage of
Ki67 positive cells was higher in 129SvEvWT CM than Stat1-nullCM or BM (B). Data are mean ± SEM
(n = 3). *P<0.05, **P<0.01. Immunofluorescence for ZO1 (green), VINC (red), ACTIN (white) and DAPI
(blue) in SSM2UCD cells cultured in CM from 129SvEvWT (C) or CM from Stat1-null ECFP (D) shows
changes in cytological distribution of structural proteins. Scale bar = 50 μm.
doi:10.1371/journal.pone.0129895.g008
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Fig 9. 129:Stat1-null fat pad conditioned media inhibits growth of normal epithelium.OMMA-1D cell
proliferation over time (A). Cells were grown in media conditioned by epithelium-free fat pads (ECFP) taken
from either 129SvEvWT, 129:Stat1-null (Stat1-null) or PDOM-treated Stat1-nullmice, or else basal media
(BM) for 4 d. Cell proliferation was measured with a methylene blue stain assay at day 2 and day 4. Data are
mean ± SEM (n = 6 wells per treatment). For 129SvEvWT vs Stat1-null, ***P<0.001 (day 2), **P<0.01 (day
4). For 129SvEvWT vs Stat1-null (PDOM), **P<0.01 (day 2). For Stat1-null vs Stat1-null (PDOM), *P<0.05
(day 2) and **P<0.01 (day 4). Data are representative of 4 separate experiments. Medium conditioned by
ECFP from 129SvEvWT or Stat1-nullmice were used to assess cytokines by Milliplex assay (B). The heat
map shows the cytokine levels of CMmade with ECFP from 129SvEvWT, Stat1-null, or Stat1-nullmice
treated with PDOM. Stat1-null gland-intact mammary fat pads (MFP) have lower levels of cytokine
expression than 129SvEvWT gland-intact MFP (C). Heat maps of multiplex cytokine/chemokine assay
results show the differences in cytokine expression levels between 129SvEvWT and Stat1-null gland-intact
MFP.
doi:10.1371/journal.pone.0129895.g009
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analysis of ECFP CM, showed reduced levels of many cytokines in the 129:Stat1-nullMFP
compared with the 129SvEv WTMFP, including G-CSF, IL-6, MSP1, KC, and MIP2 (Fig 9B).
Other cytokine levels in the 129:Stat1-null CM, such as CCL11 (eotaxin), were similar to those
in 129SvEv WT CM. Of note, the medium conditioned by ECFPs from PDOM-treated mice
exhibited cytokine profiles much closer to that from 129SvEv WT than 129:Stat1-null CM. No-
tably, there was a greater than 50-fold difference in CCL4 (MIP-1β) between Stat1-null CM
and PDOM pretreated 129:Stat1-null CM, or 129SvEv WT CM (Fig 9B). These results indicate
that the microenvironment of the ECFP in 129:Stat1-nullmice is deficient for a large range of
growth-regulatory molecules that are restored in response to PDOM.
Discussion
Our studies document a number of developmental abnormalities in MG of nulliparous 129:
Stat1-nullmice, including delayed ductal elongation and defective branching morphogenesis
that could be rescued with pregnancy and lactation. These structural abnormalities are accom-
panied by abnormal, enlarged terminal end buds with disorganized clusters of cells in the sur-
rounding stroma. Subsequently, 129:Stat1-nullmice were found to have low levels of cytokines
that likely explains the inability of the MFP to sustain growth of primary and transplanted
mammary epithelial normal and neoplastic cells. The growth-limiting deficit in the 129:Stat1-
nullMFP can, in part, be overcome with pregnancy or exogenous PDOM that restores the
cytokine profile within the MFP and reverses the epithelial growth and development defects.
However, the loss of STAT1 is also associated with minor, but statistically significant, PDOM-
resistant abnormality in branching morphogenesis that suggests an epithelial cell-autonomous
defect These phenomena highlight multiple potential roles for STAT1 in regulating the com-
plex interplay between the endocrine and stromal environments during MG development.
The comparison of MG development in 129SvEv WT and 129:Stat1-null females also re-
veals clear morphological differences between the genotypes. The 3D structural analysis of
whole mounts from six-week-old mice documents that the 129:Stat1-nullmice have larger
TEBs and a widely-dispersed overabundance of adjacent stromal “escort cells”. The presence of
these large TEB surrounded by scattered small stromal cells suggests that the signals necessary
to organize and coordinate the complex interactions between stroma and epithelium during
ductal extension may be weak or missing in nullmice.
The MGs of mature virgin 129:Stat1-null females are also underdeveloped with reduced
ductal branching that persisted beyond sexual maturity. However, the 129:Stat1-null females
can successfully nurse pups with structurally normal and functional MGs during lactation, in-
dicating that the phenotypic abnormality is reversible with hormone stimulation.
Given the global role of JAK-STAT [33] in the MGs of nulliparous females and during post-
weaning involution [42], it is somewhat surprising that previous studies did not perform de-
tailed analyses of MG development, but chose to primarily focus on tumorigenesis [12–15].
This discrepancy was also intimated by Haricharan and Li [6]. Neither Raven et al. nor Chan
et al. specifically presented data on the Stat1-null non-neoplastic MGs [12, 14]. When evaluat-
ing MG whole mounts from 50-day-old nulliparous females, Schneckenleithner et al. descri-
bed”. . .an increased density of ductal structures but no differences in end duct formation” and
showed the normal histology in a regressing Balb/c wild type MG [15]. In contrast, Klover et al.
did not report significant differences in the MGs of their epithelial-specific FVB:Stat1-null
mice, thereby implying there were no cell-intrinsic abnormalities [13]. However, the image pre-
sented by Klover et al. as evidence for their statement that “A complete lack of STAT1 expres-
sion is observed in Stat1fl/fl NIC mice” was illustrated in Fig 4 in “Non–tumor-containing
epithelium from approximately 1 year-old tumor-bearing mice is shown.” The epithelium
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illustrated was identified as hyperplastic and perhaps neoplastic by our experienced patholo-
gists. Further evidence was based on a WAP-Cre knockout that in and of itself would require a
pregnancy for promoter activation, which, as demonstrated in the current paper, obliterates
the Stat1-nullMG phenotype.
Differences between our present findings and the latter two reports could be due to differ-
ences in constructs, strains and genetic background of mouse models or other factors [43]. The
critical role of STAT1 in signal transduction in multiple organ systems [33] prompted us to un-
dertake a more detailed study of MG development in 129:Stat1-null females.
STAT1 is responsible for IFNγ signaling [6] and also mediates PRL signaling [44–46].
STATs 1, 3 and 5 are activated by a variety of extracellular stimuli including growth factors,
hormones and cytokines [6, 42]. Empirically, pregnancy rescued the 129:Stat1-nullMGmor-
phological phenotype, and exogenous PDOM increased growth of null epithelium in the 129:
Stat1-null hosts to an extent approaching that recorded in 129SvEv WT hosts. Significantly,
full recovery of MG growth and development required a combination of ovarian (P) and pitui-
tary (PRL) hormones, which could not be realized with the individual hormones (S1 Fig).
However, the 129:Stat1-null epithelium still demonstrated statistically significantly reduced
ductal branching, even after hormone stimulation and growth in a 129SvEv WT host (Fig 3).
This finding suggests that, while hormones can stimulate the 129:Stat1-null epithelium, the
subsequent branching abnormalities are, in part, epithelial-cell autonomous.
Reciprocal MG transplants revealed that both 129SvEv WT and 129:Stat1-null epithelium
could grow in 129SvEv WT hosts, whereas the syngeneic 129:Stat1-null hosts did not support
the same level of growth and differentiation of either epithelial genotype. STAT1 deficient mice
are immunodeficient and are susceptible to Listeria and plasmodium infections [17, 21, 22] and
have been used to study immune editing during tumorigenesis [22, 35], raising the possibility
that reduced MG growth in 129:Stat1-null females reflected systemic changes in marrow-
related cells.
Bone marrow-derived immune cells, particularly monocyte/macrophages, are important for
mammary duct elongation at the terminal end bud [37, 47]. However, reciprocal bone marrow
transplantation demonstrated that the impaired MG development in nulliparous 129:Stat1-null
mice is not dependent upon the immune cells themselves, but is more likely to reflect a defect
in recruitment of these cells by an altered microenvironment. The epithelial response to these
stromal abnormalities is also not limited to “normal” 129:Stat1-null epithelial cells given that
129:Stat1-null neoplastic cells transplanted into both 129SvEv WT and 129:Stat1-null hosts
grew more rapidly in 129SvEv WT hosts. Notably, the early 129:Stat1-null host response to the
tumor cells was characteristically granulocytic while the early host response in 129SvEv WT
was mononuclear and dominated by CD3+ T-cells. Such observations are consistent with
known immunological deficiencies in the 129:Stat1-nullmice having defects in the function of
NK cells and macrophages [35, 36], and further confirm that the MGmicroenvironment is al-
tered between WT and 129:Stat1-nullmice.
The biological complexity of the JAK-STAT interactions should also influence the interpre-
tation of tumorigenesis in nulliparous and parous 129:Stat1-null females in comparison to
other STAT1 models. The 129:Stat1-null females develop mammary tumors having a unique
ER+, progesterone receptor (PR)+ histological signature distinct from other models [12, 38].
Prior studies of mammary tumorigenesis in Stat1-nullmice in other mouse strains [13–15] and
using different molecular constructs [48] have induced tumors either by crossing mice with
tumor-prone cNeu transgenic mice [13–15] or by pregnancy [15]. In contrast, tumors develop
spontaneously in 129:Stat1-null nulliparous females [12].
Using transplants of normal mammary epithelium coupled with parity induction of tumori-
genesis in the Balb/c model, Schneckenleithner et al. suggested that the immune response and
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cell-intrinsic factors are important during tumorigenesis induced by loss of STAT1 [15]. Our
data are consistent with these general conclusions. However, the histopathology of the sponta-
neous ovarian dependent tumors in the 129:Stat1-nullMG is homogeneous with a unique cy-
tological ER+ phenotype [12]. In contrast, the “spontaneous” precancerous lesions (referred to
as “MIN”) and tumors in the parity-induced Balb/c model are described as heterogeneous [15].
Unfortunately, the descriptions of those lesions used human-based classifications that are diffi-
cult to translate to traditional or current mouse mammary tumor classifications [49–51]. Ex-
amination of the images in the Schneckenleithner et al. publication suggests that the
heterogeneous tumors bear hallmarks consistent with those previously documented in animals
infected with Mouse Mammary Tumor Virus (MMTV) [49, 52, 53] and described in genetical-
ly engineered mice with perturbation of the Wnt pathway [54]. Since the WT multiparous
Balb/c mice used in those studies also developed mammary tumors, it is possible that the colo-
ny is expressing the nodule inducing virus (NIV) type of MMTV found in C3Hf and some
BALB/c colonies [53], which would further confound comparisons between the different Stat1-
null models.
Profiling of the cytokines within three types of cell-free medium conditioned by cultured ex-
plants of MFP revealed a global and profound diminution of cytokines in the 129:Stat1-null
CM. Notably, the cytokine expression profiles from intact 129:Stat1-nullMGs were compara-
ble to those of the CM prepared using only the ECFP. Of note, the cytokines eotaxin (CCL11),
CSF, and MIP-1α (CCL3) are related to eosinophil or macrophage functions, which aligns with
the short-term (14 d) immunological responses within transplants of 129:Stat1-null tumors
into 129SvEv WT and 129:Stat1-null hosts.
We, and others, previously showed that diffusible unsaturated fatty acids are a major com-
ponent of the mitogenic capacity of CM prepared using explants of MFP [41, 55]. This consid-
eration raises the question of whether the metabolic capacity of the 129:Stat1-nullMFP is
modified, and whether this property is affected by the altered profile of microenvironmental
cytokines. Certainly STAT1 is crucial for adipocyte function where it mediates IFNγ-regulated
lipolysis in adipocytes [56] and the effects of prostaglandins on their differentiation [57]. At
the same time we found that both the cytokine profile and mitogenic capacity of CM could be
restored by exogenous PDOM. We [32, 58] and others [59] have highlighted the potential for
convergence of P and PRL signaling in the MG, where P alone can stimulate ductal develop-
ment in the MG [60, 61], likely via synergy with IGF-1 [62]. Along these same lines, we showed
that P and PRL synergized to stimulate proliferation of the mammary ductal epithelium of
mice independent of E [32]. Furthermore, P and PRL are both known to signal via STAT1 [46,
63], and both P and PRL can affect the activity of adipose tissue and its local production of cy-
tokines [64–66]. Thus, an evolving hypothesis is that the nulliparous 129:Stat1-nullMFP lacks
diffusible molecules such as cytokines and/or fatty acids that are required to sustain normal
mammary growth and development, and that these are locally mediated by endocrine cues dur-
ing ductal elongation. Further studies are required to dissect this complex hormonal, tissue, cel-
lular and molecular milieu and are beyond the scope of this paper.
Finally, all these factors will need to be considered in any study of tumorigenesis in STAT1
deficient mice, where our data indicate that aberrant MG development directed by the 129:
Stat1-nullmicroenvironment leads to increased tumor initiation. Since 129:Stat1-nullmice
model neoplastic development of ER-positive mammary tumors later in human life, the model
warrants further attention. A major challenge will be to determine how a neoplastic cell arises
and how it continues to grow in the relatively unsupportive 129:Stat1-null growth microenvi-
ronment. At this stage it seems unlikely that simple cell-autonomous over-expression of
growth-promoting genes can sufficiently explain neoplastic progression. The enigma that
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remains to be solved is which tumor cell-host microenvironment interactions are at play dur-
ing tumor initiation versus progression.
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